Mitchell Woods Pharmaceuticals

Mitchell Woods Pharmaceuticals is a biotechnology company focused on the development of novel small molecule therapeutics for central nervous system (CNS) disorders and oncology. The company's research, led by Chief Scientific Officer Irving Wainer, centers on the pharmacological potential of ketamine metabolites and fenoterol analogues. Key programs include the development of (2R,6R)-hydroxynorketamine (HNK) as a rapid-acting antidepressant and (R,R')-4'-methoxy-1-naphthylfenoterol (MNF) as a GPR55 antagonist for the treatment of pancreatic and brain cancers. Mitchell Woods Pharmaceuticals leverages its expertise in chiral chromatography and molecular pharmacology to target complex pathways such as the Warburg effect and GPR55-mediated signaling. The company has established collaborations with the National Institutes of Health and various academic institutions to advance its pipeline of precision medicines.